Published in BMC Syst Biol on October 04, 2011
Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal (2013) 1.10
Logic-based models in systems biology: a predictive and parameter-free network analysis method. Integr Biol (Camb) (2012) 0.90
Inferring the Effects of Honokiol on the Notch Signaling Pathway in SW480 Colon Cancer Cells. Cancer Inform (2014) 0.82
Implications of systemic dysfunction for the etiology of malignancy. Gene Regul Syst Bio (2013) 0.78
Retroactive signaling in short signaling pathways. PLoS One (2012) 0.78
Signaling cascades transmit information downstream and upstream but unlikely simultaneously. BMC Syst Biol (2016) 0.77
TEC and MAPK Kinase Signalling Pathways in T helper (TH) cell Development, TH2 Differentiation and Allergic Asthma. J Clin Cell Immunol (2012) 0.77
An argument for mechanism-based statistical inference in cancer. Hum Genet (2014) 0.77
Network-level effects of kinase inhibitors modulate TNF-α-induced apoptosis in the intestinal epithelium. Sci Signal (2015) 0.76
Detecting kinase activities from single cell lysate using concentration-enhanced mobility shift assay. Anal Chem (2014) 0.75
An amplified sensitivity arising from covalent modification in biological systems. Proc Natl Acad Sci U S A (1981) 10.04
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1996) 8.33
Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet (2004) 8.30
Targeted cancer therapy. Nature (2004) 7.81
Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol (2006) 7.25
BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol (2010) 5.75
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol (2008) 5.11
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Robust, tunable biological oscillations from interlinked positive and negative feedback loops. Science (2008) 4.45
The JAK/STAT signaling pathway. J Cell Sci (2004) 4.23
Amplification and adaptation in regulatory and sensory systems. Science (1982) 4.19
Modular cell biology: retroactivity and insulation. Mol Syst Biol (2008) 3.11
Steady states and oscillations in the p53/Mdm2 network. Cell Cycle (2005) 2.45
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
How robust are switches in intracellular signaling cascades? J Theor Biol (2003) 1.47
A hidden feedback in signaling cascades is revealed. PLoS Comput Biol (2008) 1.41
A theoretical framework for specificity in cell signaling. Mol Syst Biol (2005) 1.27
Substrate-dependent control of MAPK phosphorylation in vivo. Mol Syst Biol (2011) 1.26
Signaling properties of a covalent modification cycle are altered by a downstream target. Proc Natl Acad Sci U S A (2010) 1.24
Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol (2008) 1.18
On the role of cell signaling models in cancer research. Cancer Res (2009) 1.01
Long signaling cascades tend to attenuate retroactivity. Biophys J (2011) 0.92
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res (2006) 2.58
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene (2002) 2.02
Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res Treat (2009) 1.98
CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther (2007) 1.80
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol (2002) 1.79
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res (2002) 1.73
Load-induced modulation of signal transduction networks. Sci Signal (2011) 1.67
Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res (2006) 1.54
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res (2004) 1.51
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat (2005) 1.49
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol (2008) 1.48
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev (2002) 1.47
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia (2005) 1.42
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res (2005) 1.41
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res (2003) 1.40
Urban-rural differences in breast cancer incidence in Egypt (1999-2006). Breast (2010) 1.40
Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol (2009) 1.35
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia (2004) 1.35
Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat (2005) 1.29
Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res (2003) 1.29
Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer (2004) 1.26
RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat (2004) 1.25
RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha. J Biol Chem (2008) 1.25
High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt. Breast J (2009) 1.24
Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res (2006) 1.24
Signaling properties of a covalent modification cycle are altered by a downstream target. Proc Natl Acad Sci U S A (2010) 1.24
Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet A (2005) 1.21
Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer (2010) 1.20
RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res (2006) 1.19
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
RhoC expression and head and neck cancer metastasis. Mol Cancer Res (2009) 1.16
Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res (2011) 1.16
p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res (2011) 1.15
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther (2003) 1.15
Molecular determinants of the inflammatory breast cancer phenotype. Oncology (Williston Park) (2008) 1.12
Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res (2005) 1.12
Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw (2015) 1.12
Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients. Breast (2009) 1.11
Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat (2007) 1.11
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis (2002) 1.10
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat (2010) 1.10
Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano (2012) 1.08
RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One (2012) 1.06
Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Mol Cancer (2005) 1.05
Clinical and epidemiologic profile of breast cancer in Tanzania. Breast Dis (2010) 1.05
CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs (2007) 1.04
Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women. Breast Cancer Res Treat (2008) 1.04
Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther (2007) 1.03
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther (2003) 1.03
Multisite phosphorylation provides an effective and flexible mechanism for switch-like protein degradation. PLoS One (2010) 1.02
On the role of cell signaling models in cancer research. Cancer Res (2009) 1.01
Picosecond-resolution fluorescence lifetime imaging microscopy: a useful tool for sensing molecular interactions in vivo via FRET. Opt Express (2007) 0.99
Control of copper status for cancer therapy. Curr Cancer Drug Targets (2005) 0.99
Quantifying calcium fluxes underlying calcium puffs in Xenopus laevis oocytes. Cell Calcium (2010) 0.98
Knowledge gained after a brief CME module on breast cancer diagnosis. J Cancer Educ (2006) 0.97
Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. Breast Cancer Res Treat (2012) 0.96
Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia (2002) 0.96
Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007. Cancer Epidemiol Biomarkers Prev (2011) 0.96
Physiological fluorescence lifetime imaging microscopy improves Förster resonance energy transfer detection in living cells. J Biomed Opt (2010) 0.95
Genetic determinants of aggressive breast cancer. Annu Rev Med (2008) 0.94
Trends in Breast Cancer Incidence Rates by Age and Stage at Diagnosis in Gharbiah, Egypt, over 10 Years (1999-2008). J Cancer Epidemiol (2013) 0.94
Establishing effective registration systems in resource-limited settings: cancer registration in Kumasi, Ghana. J Registry Manag (2013) 0.94
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs (2008) 0.93
Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med Hypotheses (2009) 0.93
Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat (2011) 0.93
Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts. Mod Pathol (2002) 0.92
Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer (2010) 0.92
Long signaling cascades tend to attenuate retroactivity. Biophys J (2011) 0.92
Logic-based models in systems biology: a predictive and parameter-free network analysis method. Integr Biol (Camb) (2012) 0.90
Public and professional educational needs for downstaging breast cancer in Egypt. J Cancer Educ (2012) 0.89
Breast cancer risk reduction. J Natl Compr Canc Netw (2010) 0.88
Trends in breast cancer stage and mortality in Michigan (1992-2009) by race, socioeconomic status, and area healthcare resources. PLoS One (2013) 0.87
Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. Oncol Nurs Forum (2011) 0.86
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia (2002) 0.86
Traditional herbalists and cancer management in Kumasi, Ghana. J Cancer Educ (2012) 0.86
Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer. Cancer Res (2009) 0.86
Promoters of and barriers to cervical cancer screening in a rural setting in Tanzania. Int J Gynaecol Obstet (2013) 0.85
Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report. Am J Clin Oncol (2002) 0.85
Rho proteins and cell-matrix interactions in cancer. Cells Tissues Organs (2007) 0.84
Saltatory and continuous calcium waves and the rapid buffering approximation. Biophys J (2003) 0.84
Survival of inflammatory breast cancer patients compared to non-inflammatory breast cancer patients in Egypt. Breast J (2011) 0.83
Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients. Breast Cancer Res Treat (2011) 0.83
Characterization of the reconstituted UTase/UR-PII-NRII-NRI bicyclic signal transduction system that controls the transcription of nitrogen-regulated (Ntr) genes in Escherichia coli. Biochemistry (2012) 0.83
Pomegranate fruit extract impairs invasion and motility in human breast cancer. Integr Cancer Ther (2009) 0.82
Risk factors for chronic mastitis in morocco and egypt. Int J Inflam (2013) 0.82
Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology (2012) 0.82
Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis (2006) 0.82
Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. Integr Cancer Ther (2002) 0.81
Inflammatory breast cancer: what are the treatment options? Expert Opin Pharmacother (2009) 0.81
Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg (2003) 0.81
Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland. Clin Cancer Res (2009) 0.80